Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167219 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00167219 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 15 participants.
The verdict
NCT00167219, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The investigators hypothesize that long-term disease-free survival (DFS) in patients with JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan (L-PAM) followed by hematopoietic cell transplantation (HCT).
Interventions
- DRUG Preparative Regimen
- BIOLOGICAL Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 1999-11-18 |
| Est. Completion | 2023-08-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00167219
The ClinicalTrials.gov registry entry for NCT00167219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Preparative Regimen is the first listed.
NCT00167219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00167219 about?
NCT00167219 is a clinical study titled "Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)". The investigators hypothesize that long-term disease-free survival (DFS) in patients with JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan (L-PAM) followed by hematopoietic cell transplantation (HCT).
What is the current status of trial NCT00167219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 1999-11-18. Estimated completion is 2023-08-09.
What interventions are being tested in trial NCT00167219?
The interventions under investigation include: Preparative Regimen (DRUG), Stem Cell Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00167219?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.